147 related articles for article (PubMed ID: 33063250)
21. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
22. A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake.
Galbiati A; Zana A; Bocci M; Millul J; Elsayed A; Mock J; Neri D; Cazzamalli S
J Nucl Med; 2022 Dec; 63(12):1852-1858. PubMed ID: 35589404
[TBL] [Abstract][Full Text] [Related]
23. In vivo and in vitro evaluation of
Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
[TBL] [Abstract][Full Text] [Related]
24. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of new GnRH-I receptor radionuclide therapy with
Zoghi M; Attar Nosrati S; Rogni F; Shirvani G; Johari Daha F
J Labelled Comp Radiopharm; 2019 Jun; 62(7):310-320. PubMed ID: 31033025
[TBL] [Abstract][Full Text] [Related]
26. Proof of Therapeutic Efficacy of a
Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Stöber F; Noriega M; Pethe A; Lukas M; Osterkamp F; Reineke U; Höhne A; Smerling C; Amthauer H
J Nucl Med; 2017 Jun; 58(6):936-941. PubMed ID: 28254866
[TBL] [Abstract][Full Text] [Related]
27. Preclinical development of small-molecular-weight folate-based radioconjugates: a pharmacological perspective.
Siwowska K; Müller C
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):269-86. PubMed ID: 26149341
[TBL] [Abstract][Full Text] [Related]
28. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
29. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
Persson M; Tolmachev V; Andersson K; Gedda L; Sandström M; Carlsson J
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1457-62. PubMed ID: 16193312
[TBL] [Abstract][Full Text] [Related]
30. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
31. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Potential of
Siwowska K; Guzik P; Domnanich KA; Monné Rodríguez JM; Bernhardt P; Ponsard B; Hasler R; Borgna F; Schibli R; Köster U; van der Meulen NP; Müller C
Pharmaceutics; 2019 Aug; 11(8):. PubMed ID: 31434360
[TBL] [Abstract][Full Text] [Related]
33. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
[No Abstract] [Full Text] [Related]
35. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
36. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
37. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
38. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
39.
Pirooznia N; Abdi K; Beiki D; Emami F; Arab SS; Sabzevari O; Soltani-Gooshkhaneh S
Bioorg Chem; 2020 Sep; 102():104100. PubMed ID: 32711088
[TBL] [Abstract][Full Text] [Related]
40. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
Das T; Chakraborty S; Sarma HD; Banerjee S; Venakatesh M
Nucl Med Biol; 2010 Jul; 37(5):655-63. PubMed ID: 20610170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]